• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[中国乌鲁木齐地区1310例心房颤动患者的临床分析]

[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].

作者信息

Guo Xiaohua, Zhang Yu, Xu Guojun, Zhou Xianhui, Li Lei, Tang Baopeng

机构信息

Department of Cardiology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.

Department of Cardiology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China. Email:

出版信息

Zhonghua Nei Ke Za Zhi. 2014 May;53(5):371-4.

PMID:25146403
Abstract

OBJECTIVE

To investigate the clinical features and current therapy of atrial fibrillation (AF) of inpatients in Urumqi, China.

METHODS

The clinical data of inpatients diagnosed with AF from January, 2008 to December, 2012, in 12 hospitals in Urumqi were retrospectively analyzed.

RESULTS

Totally 1 310 AF inpatients were enrolled in this study with the age of (64.8 ± 3.3) years old and a men to women ratio of 1.39. Most patients were in age groups of 61-70 years (26.5%) and 71-80 years (27.6%). More patients with paroxysmal AF were at cardiac function class I-II (75.2%), while more patients with persistent AF were at cardiac function class III-IV (31.0%) (both P values < 0.05). The most common co-morbidities of AF were hypertension (49.2%), coronary heart disease (38.5%), diabetes mellitus (20.1%). Compared with patients of chronic AF, the patients of paroxysmal AF had higher success rates in amiodarone conversation and sinus rhythm maintenance after ablation (44.8% vs 29.9%, 87.5% vs 68.9%, P values < 0.05). Among the 1 310 inpatients, 992 patients (75.7%) received antithrombotic therapy. There were statistically significant differences in CHA2DS2 score and incidence rate of cerebral infarction among patients receiving aspirin, warfarin or rivaroxaban/other anticoagulation drugs [2(1, 3) vs 3(2, 4) vs 3(2, 5) and 6.3% vs 23.8% vs 30.2%, both P values < 0.05].

CONCLUSION

Our results of AF inpatients' age, gender, related disease distribution, AF types, incidence of stoke, therapeutic and epidemiological features are in accordance with the domestic and abroad reports.

摘要

目的

探讨中国乌鲁木齐住院心房颤动(房颤)患者的临床特征及当前治疗情况。

方法

回顾性分析2008年1月至2012年12月乌鲁木齐12家医院诊断为房颤的住院患者的临床资料。

结果

本研究共纳入1310例房颤住院患者,年龄为(64.8±3.3)岁,男女比例为1.39。大多数患者年龄在61 - 70岁组(26.5%)和71 - 80岁组(27.6%)。阵发性房颤患者心功能Ⅰ - Ⅱ级者较多(75.2%),而持续性房颤患者心功能Ⅲ - Ⅳ级者较多(31.0%)(P值均<0.05)。房颤最常见的合并症为高血压(49.2%)、冠心病(38.5%)、糖尿病(20.1%)。与慢性房颤患者相比,阵发性房颤患者在胺碘酮转复及消融术后窦性心律维持方面成功率更高(44.8%对29.9%,87.5%对68.9%,P值<0.05)。在1310例住院患者中,992例(75.7%)接受了抗栓治疗。接受阿司匹林、华法林或利伐沙班/其他抗凝药物治疗的患者在CHA2DS2评分及脑梗死发生率方面存在统计学显著差异[2(1,3)对3(2,4)对3(2,5)以及6.3%对23.8%对30.2%,P值均<0.05]。

结论

我们关于房颤住院患者的年龄、性别、相关疾病分布、房颤类型、卒中发生率、治疗及流行病学特征的结果与国内外报道一致。

相似文献

1
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].[中国乌鲁木齐地区1310例心房颤动患者的临床分析]
Zhonghua Nei Ke Za Zhi. 2014 May;53(5):371-4.
2
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.接受口服抗凝治疗的房颤患者抗心律失常治疗的应用及结果:ROCKET AF试验的结果
Heart Rhythm. 2014 Jun;11(6):925-32. doi: 10.1016/j.hrthm.2014.03.006. Epub 2014 May 13.
3
Evaluation of atrial fibrillation management and cardiovascular risk profile in atrial fibrillation patients: A cross-sectional survey.心房颤动患者的心房颤动管理及心血管风险状况评估:一项横断面调查
Medicina (Kaunas). 2017;53(1):19-25. doi: 10.1016/j.medici.2017.01.005. Epub 2017 Feb 20.
4
Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation.中国新发房颤患者使用阿司匹林和华法林对卒中及出血事件的时间趋势
Chest. 2015 Jul;148(1):62-72. doi: 10.1378/chest.14-2018.
5
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.肾功能障碍作为非瓣膜性心房颤动患者中风和全身性栓塞的预测因子:ROCKET AF(利伐沙班每日一次,口服,直接 Xa 因子抑制与维生素 K 拮抗剂预防中风和房颤试验)和 ATRIA(心房颤动抗凝和危险因素)研究队列中 R(2)CHADS(2)指数的验证。
Circulation. 2013 Jan 15;127(2):224-32. doi: 10.1161/CIRCULATIONAHA.112.107128. Epub 2012 Dec 3.
6
Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.接受射频消融治疗心房颤动的患者中,不停用利伐沙班进行围手术期抗凝的可行性和安全性:多中心前瞻性注册研究结果。
J Am Coll Cardiol. 2014 Mar 18;63(10):982-8. doi: 10.1016/j.jacc.2013.11.039. Epub 2014 Jan 8.
7
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).心房颤动的抗栓治疗:美国胸科医师学会循证临床实践指南(第8版)
Chest. 2008 Jun;133(6 Suppl):546S-592S. doi: 10.1378/chest.08-0678.
8
A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry.一项在欧洲心脏病学会成员国中进行的关于心房颤动管理的前瞻性调查:EURObservational Research Programme Atrial Fibrillation(EORP-AF)试点综合登记处的基线结果。
Europace. 2014 Mar;16(3):308-19. doi: 10.1093/europace/eut373. Epub 2013 Dec 17.
9
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).地高辛在伴有不良心血管结局的心房颤动患者中的应用:利伐沙班每日一次口服直接 Xa 因子抑制剂与维生素 K 拮抗剂预防心房颤动卒中及栓塞的临床试验(ROCKET AF)的回顾性分析。
Lancet. 2015 Jun 13;385(9985):2363-70. doi: 10.1016/S0140-6736(14)61836-5. Epub 2015 Mar 6.
10
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).与新型口服抗凝药用于新发房颤患者预防卒中相关的因素:房颤更好知情治疗结局登记研究II(ORBIT-AF II)的结果
Am Heart J. 2017 Jul;189:40-47. doi: 10.1016/j.ahj.2017.03.024. Epub 2017 Apr 4.